EUCTR2016-001529-15-IT进行中（未招募）1 期
Randomized Anticoagulation Trial In Opcab HIGH DOSE VERSUS LOW DOSE HEPARINIZATION IN PATIENTS - Randomized Anticoagulation Trial In Opcab
AZIENDA SOCIO-SANITARIA TERRITORIALE DI LECCO (ASST LECCO)0 个研究点目标入组 900 人开始时间: 2021年9月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All consecutive patients undergoing elective multivessel OPCAB, aged >18 years, of both sexes
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 600
排除标准
- •Exclusion criteria are represented by the diagnosis of acute coronary syndrome, on-going double anti-platelets treatment (the second antiplatelet drug should be suspended 5 days before surgery), on-going intravenous heparinization or sub-cutaneous low molecular weight heparin (LMWH), known coagulopathy, documented liver disease, chronic renal failure (creatinine = 2 mg/dl) or previous renal transplantation surgery, previous cardiac surgery.
研究者
相似试验
招募中
不适用
Randomized study of anti-coagulant therapy to preventpostoperative deep venous thrombosis/pulmonary embolismPatients after diegstive surgery classified high risk in DVT/PE prevention guide lineJPRN-UMIN000002444unversity of tokushima, surgery300
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial FibrillationEUCTR2005-003894-26-PTBoehringer Ingelheim Pharma GmbH & Co. KG15,000
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial FibrillationEUCTR2005-003894-26-DKBoehringer Ingelheim Pharma GmbH & Co KG18,000
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial FibrillationEUCTR2005-003894-26-DEBoehringer Ingelheim Pharma GmbH & Co. KG18,000
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYEUCTR2005-003894-26-SEBoehringer Ingelheim AB15,000